Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 5
2001 9
2002 9
2003 14
2004 11
2005 17
2006 19
2007 20
2008 18
2009 24
2010 29
2011 32
2012 27
2013 40
2014 47
2015 39
2016 44
2017 50
2018 59
2019 46
2020 54
2021 74
2022 57
2023 65
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

755 results

Results by year

Filters applied: . Clear all
Page 1
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, Anselmo A, Ummarino A, Gandoy S, Expósito F, Redrado M, Serrano D, Calvo A, Martens M, Bravo S, Mantovani A, Allavena P, Andón FT. Anfray C, et al. J Immunother Cancer. 2021 Sep;9(9):e002408. doi: 10.1136/jitc-2021-002408. J Immunother Cancer. 2021. PMID: 34531246 Free PMC article.
Previous studies have evaluated the antitumoral immune response triggered by (TLR) agonists, such as poly(I:C), imiquimod (R837) or resiquimod (R848) as monotherapies; however, their combination for the treatment of cancer has not been explored. ...
Previous studies have evaluated the antitumoral immune response triggered by (TLR) agonists, such as poly(I:C), imiquimod (R837) or resiq …
Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment.
Tambunlertchai S, Geary SM, Salem AK. Tambunlertchai S, et al. Pharmaceutics. 2022 Sep 29;14(10):2076. doi: 10.3390/pharmaceutics14102076. Pharmaceutics. 2022. PMID: 36297510 Free PMC article. Review.
One such treatment that has been tested is topical 5% imiquimod (IMQ) cream, which, although showing promise as a treatment for melanoma, has been found to have undesirable off-target effects. Resiquimod (RSQ) is an immunomodulatory molecule that can activate immune respon …
One such treatment that has been tested is topical 5% imiquimod (IMQ) cream, which, although showing promise as a treatment for melanoma, ha …
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8(+) T cells to boost anti-PD-1 therapy.
Zhang X, Wei Z, Yong T, Li S, Bie N, Li J, Li X, Liu H, Xu H, Yan Y, Zhang B, Chen X, Yang X, Gan L. Zhang X, et al. Nat Commun. 2023 Sep 13;14(1):5653. doi: 10.1038/s41467-023-41438-9. Nat Commun. 2023. PMID: 37704614 Free PMC article.
Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R848@M2pep-MPs(AFP)) for enhanced anti-PD-1 therapy in HCC. ...
Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R …
Resiquimod, a topical drug for viral skin lesions and skin cancer.
Meyer T, Surber C, French LE, Stockfleth E. Meyer T, et al. Expert Opin Investig Drugs. 2013 Jan;22(1):149-59. doi: 10.1517/13543784.2013.749236. Epub 2012 Dec 4. Expert Opin Investig Drugs. 2013. PMID: 23205468 Review.
AREAS COVERED: Studies on genital herpes, hepatitis C and actinic keratosis (AK) as well as papers of molecular activities of resiquimod were identified by a PubMed search. Although effective against genital HSV-2 in animal models, development of topical resiquimod …
AREAS COVERED: Studies on genital herpes, hepatitis C and actinic keratosis (AK) as well as papers of molecular activities of resiquimod …
Resiquimod 3M.
Jones T. Jones T. Curr Opin Investig Drugs. 2003 Feb;4(2):214-8. Curr Opin Investig Drugs. 2003. PMID: 12669385 Review.
3M Pharmaceuticals is developing a topical formulation of resiquimod as an immunomodulator for the potential treatment of herpes simplex virus (HSV) infections. As of September 2001, resiquimod was to be commercialized worldwide in association with Eli Lilly. ...
3M Pharmaceuticals is developing a topical formulation of resiquimod as an immunomodulator for the potential treatment of herpes simp …
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
Farr MA, Joshi TP, Lewis DJ. Farr MA, et al. Expert Opin Emerg Drugs. 2021 Dec;26(4):433-434. doi: 10.1080/14728214.2021.2004694. Epub 2021 Nov 15. Expert Opin Emerg Drugs. 2021. PMID: 34749552
Given these immunologic effects, resiquimod is emerging as a new topical pharmacotherapy for actinic keratosis (AK). ...Partial clinical clearance, or disappearance of >75% of AKs, was also significantly higher in the resiquimod arms varying from 75% to 87%. Over …
Given these immunologic effects, resiquimod is emerging as a new topical pharmacotherapy for actinic keratosis (AK). ...Partial clini …
Resiquimod and other immune response modifiers as vaccine adjuvants.
Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Tomai MA, et al. Expert Rev Vaccines. 2007 Oct;6(5):835-47. doi: 10.1586/14760584.6.5.835. Expert Rev Vaccines. 2007. PMID: 17931162 Review.
Synthetic immune response modifiers, such as resiquimod, are Toll-like receptor 7 and 8 agonists that act as vaccine adjuvants, enhancing antigen-specific antibody production and skewing immunity towards a Th1 response. ...For injection, resiquimod or a similar comp …
Synthetic immune response modifiers, such as resiquimod, are Toll-like receptor 7 and 8 agonists that act as vaccine adjuvants, enhan …
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
Wu JJ, Huang DB, Tyring SK. Wu JJ, et al. Antiviral Res. 2004 Nov;64(2):79-83. doi: 10.1016/j.antiviral.2004.07.002. Antiviral Res. 2004. PMID: 15498602 Review.
The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trials were suspended due to lack of efficacy. Resiquimod shows promise for other viral infections and as a vaccine adjuvant....
The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trial …
Imiquimod and resiquimod as novel immunomodulators.
Dockrell DH, Kinghorn GR. Dockrell DH, et al. J Antimicrob Chemother. 2001 Dec;48(6):751-5. doi: 10.1093/jac/48.6.751. J Antimicrob Chemother. 2001. PMID: 11733457 Review.
Enhancing the release of endogenous cytokines is, however, an alternative approach. The imidazoquinolinamines imiquimod and resiquimod have demonstrated potency as inducers of IFN-alpha and other cytokines both in vitro and in vivo. ...Complete clearance of warts has been …
Enhancing the release of endogenous cytokines is, however, an alternative approach. The imidazoquinolinamines imiquimod and resiquimod …
755 results

Searches related to "resiquimod"